How Pancreatic Cancer Is Diagnosed

Table of Contents
View All

There are several pieces of information doctors look at in order to diagnose pancreatic cancer. Imaging tests may include a special type of abdominal CT scan, endoscopic ultrasound, MRI, or ERCP. Blood tests can look for causes of jaundice as well as tumor markers, while a medical history focusing on risk factors, along with a physical exam, is also important. A biopsy may or may not be needed, depending on other findings. After diagnosis, staging is done to determine the most appropriate treatments for the disease.

Everyone should be aware of the potential warning signs and symptoms of pancreatic cancer so they can seek a medical evaluation as early as possible. Screening may be recommended based on your risk factors.

The American Gastroenterological Association recommends that patients who are deemed to be "high risk," including those with a first-degree family history of the disease and certain genetic diseases and mutations, be screened for pancreatic cancer. Screening includes genetic testing, counseling and should be conducted in people at least 50 years of age or 10 years younger than the familial onset.

pancreatic cancer diagnosis
© Verywell, 2018

Labs and Tests

The evaluation for a possible pancreatic cancer usually begins with a careful history and physical exam. Your doctor will ask you questions about any risk factors you may have, including a family history of the disease, and will inquire about your symptoms. She will then perform a physical examination looking at your skin and eyes for evidence of jaundice; examining your abdomen for a possible mass or enlargement of your liver, or any evidence of ascites (build-up of fluid in the abdomen), and checking your records to see if you have lost weight.

Blood test abnormalities with pancreatic cancer are fairly non-specific but are sometimes helpful in making a diagnosis when combined with imaging tests. Tests may include:

  • Liver function tests, which are sometimes increased
  • A complete blood count (CBC), looking for an elevated platelet count (thrombocytosis) in particular
  • A bilirubin test. There are different types of bilirubin, and based on the specific type tested, physicians may gain clues as to the source of any jaundice you have. With obstructive jaundice (due to a pancreatic tumor pushing on the common bile duct), there are elevations in both conjugated and total bilirubin.

Blood sugar is often elevated, as up to 80% of people with pancreatic cancer will develop insulin resistance or diabetes.

Individuals who suffer from a sudden case of inflamed pancreas, also known as pancreatitis, have a higher risk of developing pancreatic cancer. Individuals with sudden-onset pancreatitis will show elevations in serum amylase and serum lipase in screening tests.

Tumor Markers

Tumor markers are proteins or other factors secreted by cancer cells and can be detected via a blood test, among other tests. According to a study, the tumor marker carcinoembryonic antigen (CEA) is elevated in roughly half of the people diagnosed with the disease. CEA is also elevated in several other types of conditions as well. CA 19-9 levels may be tested, but since they are not always elevated and raised levels can also indicate other medical conditions, this is not particularly helpful in making a diagnosis of pancreatic cancer. This result, however, is helpful in deciding if a pancreatic tumor can be removed surgically, and for following the course of treatment.

Neuroendocrine Tumor Blood Tests

Certain blood tests may also be helpful in diagnosing the rare type of pancreatic cancers referred to as neuroendocrine tumors. Unlike most pancreatic tumors, that are composed of cells that make digestive enzymes, these tumors involve endocrine cells that make hormones such as insulin, glucagon, and somatostatin. Measuring levels of these hormones, as well as conducting a few other blood tests, can be helpful in diagnosing these tumors.

Pancreatic Cancer Doctor Discussion Guide

Get our printable guide for your next doctor's appointment to help you ask the right questions.

Doctor Discussion Guide Woman


Imaging tests are usually the primary method of confirming or refuting the presence of a mass in the pancreas. Options may include:

CT Scan

Computerized tomography (CT) uses X-rays to create a cross-section of a region of the body and is often the mainstay of diagnosis. If a physician suspects pancreatic cancer specifically, a special type of CT scan called a multiphase helical CT scan or pancreatic protocol CT scan is often recommended.

A CT scan can be helpful both for characterizing the tumor (determining its size and location in the pancreas) and looking for any evidence of spread to lymph nodes or other regions. CT may be more effective than endoscopic ultrasound in determining whether cancer has spread to the superior mesenteric artery (important in choosing treatment).

Endoscopic Ultrasound (EUS)

Ultrasound uses sound waves to create an image of the inside of the body. A conventional (transcutaneous) ultrasound is not usually done if a doctor suspects pancreatic cancer, as intestinal gas can make visualization of the pancreas difficult. But it may be helpful when looking for other abdominal problems.

An endoscopic ultrasound can be a valuable procedure in making the diagnosis. Done via endoscopy, a flexible tube with an ultrasound probe at its end is inserted through the mouth and threaded down into the stomach or small intestine, so that the scan can be done from inside.

Because these areas are very near to the pancreas, the test allows doctors to get a very good look at the organ.

With the use of medications (conscious sedation), people usually tolerate the procedure well. The test may be more accurate than CT for assessing the size and extent of a tumor but isn't as good at finding any distant spread of the tumor (metastases) or determining if the tumor involves blood vessels.

Endoscopic Retrograde Cholangiopancreatography (ERCP)

Endoscopic retrograde cholangiopancreatography (ERCP) is a test that involves endoscopy plus X-rays in order to visualize the bile ducts. ERCP can be a sensitive test for finding pancreatic cancer but is not as accurate in differentiating the disease from other problems, such as pancreatitis. It's also an invasive procedure, similar to some of the tests described above.


Magnetic resonance imaging (MRI) uses magnets rather than X-rays to create an image of internal structures. MRI is used less often than CT with pancreatic cancer but may be used in certain circumstances. As with CT, there are special types of MRI, including MR cholangiopancreatography (MRCP). Since it hasn't been studied as much as the tests above, it's used primarily for people for whose diagnosis is unclear based on other studies, or if a person has an allergy to the contrast dye used for CT.     


A test called an octreoscan or somatostatin receptor scintigraphy (SRC) may be done if a neuroendocrine tumor of the pancreas is suspected. In an octreoscan, a radioactive protein (called a tracer) is injected into a vein. If a neuroendocrine tumor is present, the tracer will bind to cells in the tumor. Several hours later, a scan (scintigraphy) is done that picks up any radiation that is being emitted (neuroendocrine tumors will light up, if present).

PET Scan

PET scans, often combined with CT (PET/CT), may occasionally be done, but are used much less often with pancreatic cancer than with some other cancers. In this test, a small amount of radioactive sugar is injected into a vein and a scan is done after the sugar has had time to be absorbed by cells. Actively growing cells, such as cancer cells, will "light up," in contrast to areas of normal cells or scar tissue.


A sample of tissue (a biopsy) is needed to confirm the diagnosis most of the time, as well as look at the molecular characteristics of the tumor. In selected cases, surgery can be done without a biopsy.

A fine needle biopsy (a procedure in which a thin needle is directed through the skin in the abdomen and into the pancreas to extract a sample of tissue) is most often done using guidance with either ultrasound or CT.

There is some concern that this type of biopsy could "seed" the tumor, or result in the spread of the cancer along the line where the needle is introduced.

It's not known how often seeding occurs, but according to a 2017 study, the number of case reports of seeding due to endoscopic ultrasound-guided fine needle aspiration has been rapidly increasing.

Since biopsies are done primarily to see if surgery may be done (the only treatment that improves long-term survival), this is a concern worth talking about with your doctor.

As an alternative approach, laparoscopy may be used, especially if a tumor may be able to be removed (resectable). In a laparoscopy, several small incisions are made in the abdomen and a narrow instrument is inserted to perform the biopsy. This procedure can identify up to 20% of surgery candidates whose tumors are actually inoperable. Some physicians recommend utilizing this type of laparoscopy for anyone who will be having surgery (to avoid unnecessary extensive surgery).

Differential Diagnoses

There are a number of conditions that may mimic the symptoms of pancreatic cancer or result in similar findings on blood tests and imaging. Doctors will work to rule out the following before making a diagnosis:

  • Bile duct stricture, an abnormal narrowing of the bile duct. It may be caused by gallstones or surgery to remove them, but may also be caused by pancreatic cancer.
  • Acute or chronic pancreatitis, an inflammation of the pancreas, can cause similar symptoms, but does not result in a mass. Between 7% and 14% of those diagnosed with pancreatic cancer also present with acute pancreatitis.
  • Bile duct stones in the bile duct can cause symptoms of obstructive jaundice and can often be seen on ultrasound. Like bile duct strictures, however, they may be present along with pancreatic cancer.
  • Ampullary carcinoma
  • Gallbladder cancers can appear very similar to pancreatic cancers but may be differentiated with CT or MRI.
  • Gallstones (cholelithiasis)
  • Gastric or duodenal ulcers
  • Abdominal aortic aneurysm 
  • Pancreatic lymphoma
  • Gastric lymphoma
  • Liver cancer
  • Bile duct cancer 


Determining the stage of a pancreatic cancer is extremely important when it comes to deciding whether a cancer can be surgically removed or not. If staging is inaccurate, it may lead to unnecessary surgery. Staging can also assist in estimating the prognosis of the disease.

pancreatic cancer stage at diagnosis
Illustration by Verywell

TNM Staging

Doctors use a system called TNM staging to determine the stage of a tumor. This can be terribly confusing at first but is much easier to understand if you know what these letters mean.

T stands for tumor. A tumor is given a number from T1 to T4 based on the size of the tumor, as well as other structures the tumor may have invaded. For a primary tumor:

  • T1: Tumor confined to the pancreas and less than 2 cm.
  • T2: Tumor confined to the pancreas and more than 2 cm.
  • T3: Tumor extends beyond the pancreas (to the duodenum, bile duct, or mesenteric vein), but does not involve the celiac axis or superior mesenteric artery.
  • T4: Tumor involves the celiac artery or the superior mesenteric artery.

N stands for lymph nodes. N0 would mean that a tumor has not spread to any lymph nodes, meaning there is no involvement of regional lymph nodes. N1 means that the tumor has spread to nearby lymph nodes, meaning regional lymph nodes are positive for cancer.

M stands for metastases. If a tumor has not spread, it would be described as M0, meaning no distant metastasis. If it has spread to distant regions (beyond the pancreas) it would be referred to as M1.

Based on TNM, tumors are then given a stage between 0 and 4. There are also substages:

  • Stage 0: Stage 0 is also referred to as carcinoma in situ and refers to cancer that has not yet spread past something called the basement membrane. These tumors are not invasive (though subsequent stages are) and should theoretically be completely curable.
  • Stage 1: Stage 1 (T1 or T2, N0, M0) pancreatic cancers are confined to the pancreas and are less than 4 cm (about 2 inches) in diameter.
  • Stage 2: Stage 2 tumors (either T3, N0, M0 or T1-3, N1, M0) either extend beyond the pancreas (without involving the celiac axis or superior mesenteric artery) and have not spread to lymph nodes, or are confined to the pancreas but have spread to lymph nodes. 
  • Stage 3: Stage 3 tumors (T4, any N, M0) extend beyond the pancreas and involve either the celiac artery or superior mesenteric artery. They may or may not have spread to lymph nodes, but have not spread to distant regions of the body.
  • Stage 4: Stage 4 tumors (Any T, any N, M1) can be any size. While they may or may not have spread to lymph nodes, they have spread to distant sites such as the liver, the peritoneum (the membranes that line the abdominal cavity), the bones, or the lungs.
Was this page helpful?
Article Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Lee ES, Lee JM. Imaging diagnosis of pancreatic cancer: a state-of-the-art reviewWorld J Gastroenterol. 2014;20(24):7864-7877. doi:10.3748/wjg.v20.i24.7864

  2. Aslanian HR, Lee JH, Canto MI. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review [published online ahead of print, 2020 May 19]. Gastroenterology. 2020;S0016-5085(20)30657-0. doi:10.1053/j.gastro.2020.03.088

  3. Kim VM, Ahuja N. Early detection of pancreatic cancerChin J Cancer Res. 2015;27(4):321-331. doi:10.3978/j.issn.1000-9604.2015.07.03

  4. American Cancer Society. Tests for Pancreatic Cancer. Updated January 2, 2020.

  5. Kwon CI, Cho JH, Choi SH, et al. Recent advances in the diagnosis and management of chronic pancreatitisKorean J Intern Med. 2019;34(2):242-260. doi:10.3904/kjim.2019.051

  6. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg. 2003;138(9):951-955. doi:10.1001/archsurg.138.9.951

  7. Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive ReviewIndian J Surg Oncol. 2011;2(2):88-100. doi:10.1007/s13193-011-0042-1

  8. National Cancer Institute. Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version. Updated April 19, 2019.

  9. Tummala P, Junaidi O, Agarwal B. Imaging of pancreatic cancer: An overviewJ Gastrointest Oncol. 2011;2(3):168-174. doi:10.3978/j.issn.2078-6891.2011.036

  10. Squires MH, Volkan Adsay N, Schuster DM, et al. Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach. Ann Surg Oncol. 2015;22(7):2295-2301. doi:10.1245/s10434-015-4471-x

  11. Minaga K, Takenaka M, Katanuma A, et al. Needle Tract Seeding: An Overlooked Rare Complication of Endoscopic Ultrasound-Guided Fine-Needle Aspiration. Oncology. 2017;93 Suppl 1:107-112. doi:10.1159/000481235

  12. The National Pancreas Foundation. Preoperative Evaluation in Pancreatic Cancer- How much is enough? 2017.

  13. Li S, Tian B. Acute pancreatitis in patients with pancreatic cancer: Timing of surgery and survival durationMedicine (Baltimore). 2017;96(3):e5908. doi:10.1097/MD.0000000000005908

  14. National Organization for Rare Disorders. Cholangiocarcinoma. 2017.

  15. De La Cruz MSD, Young AP, Ruffin MT. Diagnosis and Management of Pancreatic Cancer. Am Fam Physician. 2014;89(8):626-632.

  16. American Cancer Society. Pancreatic Cancer Stages. Updated December 18, 2017.

Additional Reading
  • Pancreatic Cancer Diagnosis. American Society of Clinical Oncology. Cancer.Net. Updated 12/2016.

  • Aslanian HR, Lee JH, Canto MI. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review [published online ahead of print, 2020 May 19]. Gastroenterology. 2020;S0016-5085(20)30657-0. doi:10.1053/j.gastro.2020.03.088

  • Kikuyama, M., Kamisawa, T., Kuruma, S. et al. Early Diagnosis to Improve the Poor Prognosis of Pancreatic Cancer. Cancers. 2018. 10(2):.pii: E48. DOI: 10.3390/cancers10020048.

  • Current and Emerging Therapies in Pancreatic Cancer, Springer Verlag, 2017.